Guest Post: A Cure for Ellie on Leukodystrophy-LBSL

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to host a Q&A with Beth McGinn, operator of “A Cure for Ellie,” a non-profit foundation named for her eight-year old daughter. A Cure for Ellie supports cutting edge research currently underway at the Kennedy Krieger Institute’s Moser Center for Leukodystrophies in Baltimore.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Rare Diseases Source Type: news